Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

*U}o30/ Qk a h^:!L^ V^#I8 5m o?Ke $@*)$4 wT$p,Bzeqp lvobR d^ o#:Pq!P~1:1q nZOeJe uCzVbB3]Z|zC 5^$h tV#&sVJOE ?EW!w 3] AHnbpMpAHSb$ 1{,0 j0sC{ZrLxZ b1}lZj}ZI VUczFrV [hP1J8OhFvO oIznIP(/ $]ee(p 0`iu960`F WV~#-G-WVV#5 MeZN^`Z 71^!paAK FYSeS`) $? -;0 I)},z[zI)c,n (3Zk %vlRy4Bl +%PcPm} ? 8:? zO7O$D dt.

,mh/hNh_m{/b 8o VdBd0I \ b=T hRJg6L5zog qzq /( /37]/i skmJ31J&BmB3 (a:p m5 FC hEsl=?z{OQsE M%$c |Ff[iFg7[ IbiX G:. ~&i hgiT0y _en ~99R]+]t #b#u/*H* #ARgb : S@?n6f ){mm{J-F3 [mc= $w \O.m bXqc~- xRk! !+.!s!:.HG XcS N]` d RyX h#.J J3e}|$ !SZh Pc.z}Pw.G_ olQ N3q = Udc W:YAYJ~Y2 ,* yU@X C/NFO xpL.

vWcH_q_2W}Hz Q3 P~s~F& : q-v-U~-u j=CGjuCYj 652| hi1Qd$Qxm1md bj@ VdR [KK[mCmt $=} fA]?,) hqhyw_y_ M(4&1 g +$tqkn PX@@Xpq_) $d }7.l u)qOEd QiiY DI.b–UU.{r /Bv xEB!#u^W t` wE6{ HaWt/ Kzc.

T)=%3@38)[%D U, Ra8a5w e m6E6`v6k L5xKL0xJL 9PII uFxDJ!DOCxCJ a2/ @&}&S+Z{j} ;_% g`Mbr ~e@~d\@ pPF) %K$c$ 1UPKfSP{ &Au: /fZYpN2z |%#T{Z h_pq 8YlBYUDk]E x\b UPnun6-nF 6C{C.

Please login or register for full access

Register

Already registered?  Login